Is p-Tau 217 Enough?
Understanding the Alzheimer's Blood Biomarker Panel
Alzheimer's disease involves multiple biological processes that evolve over time. Combining biomarkers of amyloid biology, tau pathology, glial activation and neuroaxonal injury can provide a more multidimensional view than any single marker alone.
Different Biomarkers Answer Different Biological Questions
Amyloid accumulation, abnormal tau phosphorylation, glial activation and neuronal injury represent distinct but interconnected components of Alzheimer's disease biology.
For this reason, biomarker selection should begin with the biological question rather than simply choosing the most widely discussed marker.
Aβ42 / Aβ40 — Amyloid Biology
The ratio of amyloid-β 42 to amyloid-β 40 is widely investigated as a marker of amyloid-related biology and can help normalize some of the inter-individual variability associated with absolute peptide concentrations.
p-Tau 217 — A Leading Blood-Based AD Biomarker
Tau normally contributes to neuronal microtubule stability. In Alzheimer's disease, abnormal phosphorylation and aggregation of tau are associated with disease pathology.
Phosphorylated tau at threonine 217 has emerged as an important blood-based biomarker for Alzheimer's disease research.
Because p-Tau 217 occurs at extremely low concentrations in blood, ultrasensitive detection is particularly important for serum and plasma studies.
p-Tau 205 — Looking Further Downstream
Different phosphorylated tau species do not necessarily reflect identical stages of disease biology.
p-Tau 205 is being investigated as a marker associated with more downstream tau pathology, including mature neurofibrillary tangle burden and disease staging.
Combining different p-Tau species may therefore provide information about where a sample lies along the tau pathology continuum.
GFAP — Glial and Astrocyte Biology
Glial Fibrillary Acidic Protein (GFAP) provides a different biological perspective. It is associated with astrocyte biology and can support investigation of glial responses alongside amyloid and tau pathology.
NfL — Neuroaxonal Injury
Neurofilament Light Chain (NfL) is widely studied as a biomarker of neuroaxonal injury and neurodegeneration.
Rather than being specific to Alzheimer's disease, NfL can provide complementary information about neuronal injury.
Building a Multi-Biomarker View
| Biomarker | Biological Context |
|---|---|
| Aβ42/40 | Amyloid biology |
| p-Tau 217 | AD-related tau / amyloid-associated pathology |
| p-Tau 205 | Downstream tau pathology and staging research |
| GFAP | Astrocyte / glial biology |
| NfL | Neuroaxonal injury / neurodegeneration |
Why Ultrasensitive Detection Matters
Neurological biomarkers can occur at extremely low concentrations in peripheral blood. An assay that performs well in CSF may therefore require substantially greater sensitivity when translated to serum or plasma.
Quanterix Simoa® digital immunoassay technology is designed for ultra-low-level biomarker measurement in common biological matrices.
For example, the Simoa® p-Tau 217 Advantage PLUS assay reports an analytical LLOQ of 0.005 pg/mL and an LOD of 0.001 pg/mL for research using human serum and EDTA plasma.
This illustrates why analytical sensitivity should be considered early when designing blood-based neurological biomarker studies.
Biomarker Study Checklist
✓ Which biology is the study intended to measure?
✓ Will samples be plasma, serum or CSF?
✓ Are expected concentrations above the assay LLOQ?
✓ Should multiple phosphorylated tau species be compared?
✓ Would GFAP or NfL provide complementary information?
✓ Is longitudinal biomarker monitoring required?
✓ Is a single-plex or multiplex strategy more appropriate?
Planning an Alzheimer's or Neurodegeneration Biomarker Study?
Dana Bioscience can help source ultrasensitive immunoassay solutions for
p-Tau, amyloid beta, GFAP, NfL and other neurological biomarkers.
Share your target biomarkers, sample matrix, expected concentration range
and study objective, and we can help identify appropriate assay options.